Antifungal Dosing for Abdominal Sepsis
For intra-abdominal candidiasis with sepsis, use an echinocandin at standard loading and maintenance doses: caspofungin 70 mg loading dose then 50 mg daily, micafungin 100 mg daily, or anidulafungin 200 mg loading dose then 100 mg daily. 1
Treatment Algorithm
The 2016 IDSA guidelines explicitly state that the choice of antifungal therapy for intra-abdominal candidiasis is the same as for candidemia or empiric therapy for nonneutropenic ICU patients (strong recommendation; moderate-quality evidence). 1
First-Line Therapy Options
Echinocandins are preferred for critically ill patients:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
Fluconazole alternative (if patient is hemodynamically stable and low risk for azole-resistant species):
- 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily
Critical Decision Points
Use echinocandins (not fluconazole) when:
- Patient has septic shock or severe physiologic disturbance 1
- Recent azole exposure
- Known or suspected azole-resistant Candida species (C. glabrata, C. krusei)
- Critically ill ICU patient 2
Fluconazole may be considered only if:
- Patient is hemodynamically stable
- No recent azole exposure
- Local epidemiology shows <5% azole resistance
- C. albicans suspected
Essential Concurrent Management
Source control is mandatory (strong recommendation; moderate-quality evidence):
- Appropriate drainage and/or debridement required
- Remove infected devices/catheters within 48-72 hours if present
- Repair anastomotic leaks or perforations
Duration of Therapy
Treatment duration is determined by:
- Adequacy of source control (primary determinant)
- Clinical response
- Resolution of signs/symptoms
If source control is adequate and patient responds clinically, treat for 2 weeks after documented clearance of Candida from bloodstream (if candidemia present) and resolution of symptoms. 1
Special Considerations for Abdominal Sepsis
Why Echinocandins Are Preferred
The 2010 SIS/IDSA guidelines specifically recommend echinocandins for critically ill patients with intra-abdominal candidiasis (strong recommendation). 2 This is reinforced by the 2025 ECMM guideline stating echinocandins should be used for patients with septic shock. 3
Pharmacokinetic Concerns
Recent evidence highlights that critically ill patients with abdominal sepsis have altered pharmacokinetics that may lead to subtherapeutic antifungal levels. 4, 5 However, standard echinocandin dosing remains appropriate as initial therapy, with consideration for therapeutic drug monitoring if available.
Empiric Therapy Timing
Start antifungal therapy immediately if patient has:
- Clinical evidence of intra-abdominal infection PLUS
- Significant risk factors: recent abdominal surgery, anastomotic leaks, necrotizing pancreatitis, recurrent perforations 1
- Septic shock with risk factors for candidiasis 1, 3
Do not wait for culture confirmation in critically ill patients with septic shock. 1, 3
Common Pitfalls to Avoid
Do not use fluconazole as initial therapy in critically ill patients with septic shock—echinocandins have superior outcomes in this population. 2
Do not rely on antifungals alone—inadequate source control is associated with treatment failure regardless of antifungal choice. 1
Do not use amphotericin B as initial therapy due to toxicity unless echinocandins and azoles are contraindicated or unavailable. 2
Do not continue empiric therapy indefinitely—tailor or discontinue based on culture results and clinical response. 2
De-escalation Strategy
Once cultures return and patient is clinically stable: